Nasopharyngeal Carcinoma
Conditions
Keywords
Immunotherapy, Anti-PD-1 antibody, Nasopharyngeal Carcinoma, VEGF
Brief summary
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.
Interventions
BIOLOGICALAK105
IV infusion
DRUGCisplatin
IV infusion
DRUGGemcitabine
IV infusion
DRUGAnlotinib hydrochloride
Oral administration
Sponsors
Akeso Tiancheng, Inc
Akeso
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent form voluntarily. * Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the ICF. * Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. * Expected life expectance ≥ 3 months. * Histologically confirmed diagnosis of stage IVb NPC (AJCC 8th). * Metastatic NPC patients who have not recieved the first-line platinumbased chemotherapy. * At least one measurable tumor lesion per RECIST 1.1 criteria. * Subjects must provide an available tumor tissue sample taken within 3 years prior to enrollment. * Adequate organ function. * Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception. * Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and for 120 days after the last dose of investigational product.
Exclusion criteria
* Other invasive malignancies within 2 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ. * Is currently participating in a study of an investigational agent or using an investigational device. * Has known active central nervous system (CNS) metastases. * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment NOTE: Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. * Has an active infection requiring systemic therapy. * Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). * History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment. * Has undergone major surgery within 30 days of Study Day 1. * Has received a live virus vaccine within 30 days of the planned first dose of study therapy. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. * Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | up to 2 years | ORR is the proportion of subjects with CR or PR based on RECIST v1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | up to 2 years | DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1. |
| Duration of response (DoR) | up to 2 years | DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first. |
| Progression-free survival (PFS) | up to 2 years | PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) or death from any cause (whichever occurs first). |
| Observed concentrations of AK105 | From first dose of AK105 through 90 days after last dose of AK105. | The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration. |
| Number of subjects who develop detectable anti-drug antibodies (ADAs) | From first dose of AK105 through 90 days after last dose of AK105. | The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs). |
| Overall survival (OS) | up to 2 years | OS is defined as the time from the date of randomization to death from any cause. |
Countries
China
Outcome results
None listed